
Prema Maria Mertz
Examiner (ID: 426, Phone: (571)272-0876 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1674, 1646, 1621, 1812 |
| Total Applications | 2681 |
| Issued Applications | 1589 |
| Pending Applications | 444 |
| Abandoned Applications | 675 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18692580
[patent_doc_number] => 20230322881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => FUSION PROTEIN INCLUDING IL15 PROTEIN, IL15 RECEPTOR ALPHA PROTEIN, FC DOMAIN, AND IL2 PROTEIN, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/043395
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043395
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/043395 | FUSION PROTEIN INCLUDING IL15 PROTEIN, IL15 RECEPTOR ALPHA PROTEIN, FC DOMAIN, AND IL2 PROTEIN, AND USE THEREOF | Aug 29, 2021 | Abandoned |
Array
(
[id] => 17563172
[patent_doc_number] => 20220127321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION
[patent_app_type] => utility
[patent_app_number] => 17/458028
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33970
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458028 | ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION | Aug 25, 2021 | Abandoned |
Array
(
[id] => 17761496
[patent_doc_number] => 20220235108
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => Methods and Compositions Based on Diphtheria Toxin-Interleukin-3 Conjugates
[patent_app_type] => utility
[patent_app_number] => 17/411947
[patent_app_country] => US
[patent_app_date] => 2021-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411947
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/411947 | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates | Aug 24, 2021 | Issued |
Array
(
[id] => 19041767
[patent_doc_number] => 11930837
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Antibody-cytokine engrafted proteins and methods of use for immune related disorders
[patent_app_type] => utility
[patent_app_number] => 17/403710
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 28952
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403710
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403710 | Antibody-cytokine engrafted proteins and methods of use for immune related disorders | Aug 15, 2021 | Issued |
Array
(
[id] => 18567129
[patent_doc_number] => 20230257458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => ANTIBODY OF IL-11 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/014310
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12765
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014310
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014310 | ANTIBODY OF IL-11 AND USE THEREOF | Aug 11, 2021 | Abandoned |
Array
(
[id] => 17242082
[patent_doc_number] => 20210361825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSION
[patent_app_type] => utility
[patent_app_number] => 17/444598
[patent_app_country] => US
[patent_app_date] => 2021-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444598
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/444598 | Compositions and methods for macrophage conversion | Aug 5, 2021 | Issued |
Array
(
[id] => 19196412
[patent_doc_number] => 11993639
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-28
[patent_title] => Therapeutic IL-13 polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/388895
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 14
[patent_no_of_words] => 11794
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388895
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388895 | Therapeutic IL-13 polypeptides | Jul 28, 2021 | Issued |
Array
(
[id] => 17243493
[patent_doc_number] => 20210363236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => Anti-IL-33 Antibodies and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/388322
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388322
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388322 | Anti-IL-33 antibodies and uses thereof | Jul 28, 2021 | Issued |
Array
(
[id] => 17687711
[patent_doc_number] => 20220195003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => IL-2 MUTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/386047
[patent_app_country] => US
[patent_app_date] => 2021-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/386047 | IL-2 muteins and uses thereof | Jul 26, 2021 | Issued |
Array
(
[id] => 18837720
[patent_doc_number] => 11845783
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-19
[patent_title] => Multimeric IL-15 soluble fusion molecules and methods of making and using same
[patent_app_type] => utility
[patent_app_number] => 17/385714
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 113
[patent_figures_cnt] => 183
[patent_no_of_words] => 47974
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385714 | Multimeric IL-15 soluble fusion molecules and methods of making and using same | Jul 25, 2021 | Issued |
Array
(
[id] => 17672692
[patent_doc_number] => 20220185859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => IL-2 MUTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/385061
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385061
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385061 | IL-2 muteins and uses thereof | Jul 25, 2021 | Issued |
Array
(
[id] => 18612360
[patent_doc_number] => 20230279092
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => IMMUNOCYTOKINES FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/017005
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017005
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017005 | Immunocytokines for treatment of autoimmune and inflammatory conditions | Jul 19, 2021 | Issued |
Array
(
[id] => 18565742
[patent_doc_number] => 20230256069
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => USE OF EPIDERMAL GROWTH FACTOR DEPLETING AGENTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/018156
[patent_app_country] => US
[patent_app_date] => 2021-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1910
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018156
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018156 | USE OF EPIDERMAL GROWTH FACTOR DEPLETING AGENTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Jul 18, 2021 | Pending |
Array
(
[id] => 17200152
[patent_doc_number] => 20210340247
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/373412
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373412
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373412 | Biopharmaceutical compositions | Jul 11, 2021 | Issued |
Array
(
[id] => 17185240
[patent_doc_number] => 20210332125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => BIOPHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/373537
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373537
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373537 | Biopharmaceutical compositions | Jul 11, 2021 | Issued |
Array
(
[id] => 17467680
[patent_doc_number] => 11274148
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-15
[patent_title] => Biopharmaceutical compositions
[patent_app_type] => utility
[patent_app_number] => 17/373223
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 40980
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373223
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373223 | Biopharmaceutical compositions | Jul 11, 2021 | Issued |
Array
(
[id] => 19049341
[patent_doc_number] => 20240091310
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION AND/OR TREATMENT OF DISEASE IN MAMMALS
[patent_app_type] => utility
[patent_app_number] => 18/004631
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10312
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004631
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/004631 | COMPOSITIONS AND METHODS USEFUL FOR THE PREVENTION AND/OR TREATMENT OF DISEASE IN MAMMALS | Jul 8, 2021 | Pending |
Array
(
[id] => 17299537
[patent_doc_number] => 20210395376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127
[patent_app_type] => utility
[patent_app_number] => 17/363260
[patent_app_country] => US
[patent_app_date] => 2021-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29401
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/363260 | Antibodies and polypeptides directed against CD127 | Jun 29, 2021 | Issued |
Array
(
[id] => 17299537
[patent_doc_number] => 20210395376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127
[patent_app_type] => utility
[patent_app_number] => 17/363260
[patent_app_country] => US
[patent_app_date] => 2021-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29401
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/363260 | Antibodies and polypeptides directed against CD127 | Jun 29, 2021 | Issued |
Array
(
[id] => 20757660
[patent_doc_number] => 12650424
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-09
[patent_title] => Method and system for determining intracellular mediators' activity
[patent_app_type] => utility
[patent_app_number] => 18/007501
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 11
[patent_no_of_words] => 8489
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 282
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007501
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/007501 | Method and system for determining intracellular mediators' activity | Jun 22, 2021 | Issued |